Literature DB >> 27382021

Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition.

Takaaki Mitsui1, Miho Watanabe-Takahashi1, Eiko Shimizu1, Baihao Zhang1, Satoru Funamoto2, Shinji Yamasaki3, Kiyotaka Nishikawa4.   

Abstract

Shiga toxin (Stx), a major virulence factor of enterohemorrhagic Escherichia coli (EHEC), can be classified into two subgroups, Stx1 and Stx2, each consisting of various closely related subtypes. Stx2 subtypes Stx2a and Stx2d are highly virulent and linked with serious human disorders, such as acute encephalopathy and hemolytic-uremic syndrome. Through affinity-based screening of a tetravalent peptide library, we previously developed peptide neutralizers of Stx2a in which the structure was optimized to bind to the B-subunit pentamer. In this study, we identified Stx2d-selective neutralizers by targeting Asn16 of the B subunit, an amino acid unique to Stx2d that plays an essential role in receptor binding. We synthesized a series of tetravalent peptides on a cellulose membrane in which the core structure was exactly the same as that of peptides in the tetravalent library. A total of nine candidate motifs were selected to synthesize tetravalent forms of the peptides by screening two series of the tetravalent peptides. Five of the tetravalent peptides effectively inhibited the cytotoxicity of Stx2a and Stx2d, and notably, two of the peptides selectively inhibited Stx2d. These two tetravalent peptides bound to the Stx2d B subunit with high affinity dependent on Asn16. The mechanism of binding to the Stx2d B subunit differed from that of binding to Stx2a in that the peptides covered a relatively wide region of the receptor-binding surface. Thus, this highly optimized screening technique enables the development of subtype-selective neutralizers, which may lead to more sophisticated treatments of infections by Stx-producing EHEC.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27382021      PMCID: PMC4995913          DOI: 10.1128/IAI.00149-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d.

Authors:  J F Kokai-Kun; A R Melton-Celsa; A D O'Brien
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

2.  Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3.

Authors:  H Ling; A Boodhoo; B Hazes; M D Cummings; G D Armstrong; J L Brunton; R J Read
Journal:  Biochemistry       Date:  1998-02-17       Impact factor: 3.162

3.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

4.  Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.

Authors:  Martina Bielaszewska; Alexander W Friedrich; Thomas Aldick; Robin Schürk-Bulgrin; Helge Karch
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

5.  Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.

Authors:  Deborah J Stearns-Kurosawa; Valta Collins; Scott Freeman; Diann Debord; Kiyotaka Nishikawa; Sun-Young Oh; Caitlin S Leibowitz; Shinichiro Kurosawa
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.

Authors:  George L Mulvey; Paola Marcato; Pavel I Kitov; Joanna Sadowska; David R Bundle; Glen D Armstrong
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

8.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

9.  Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.

Authors:  Marie E Fraser; Masao Fujinaga; Maia M Cherney; Angela R Melton-Celsa; Edda M Twiddy; Alison D O'Brien; Michael N G James
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

10.  Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice.

Authors:  A R Melton-Celsa; S C Darnell; A D O'Brien
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more
  2 in total

Review 1.  Shiga Toxin Therapeutics: Beyond Neutralization.

Authors:  Gregory Hall; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2017-09-19       Impact factor: 4.546

2.  The inducible amphisome isolates viral hemagglutinin and defends against influenza A virus infection.

Authors:  Jumpei Omi; Miho Watanabe-Takahashi; Katsura Igai; Eiko Shimizu; Ching-Yi Tseng; Tomohiro Miyasaka; Tsuyoshi Waku; Shinichiro Hama; Rieka Nakanishi; Yuki Goto; Yuri Nishino; Atsuo Miyazawa; Yasuhiro Natori; Makoto Yamashita; Kiyotaka Nishikawa
Journal:  Nat Commun       Date:  2020-01-09       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.